Quadrant Capital Group LLC Fate Therapeutics Inc Transaction History
Quadrant Capital Group LLC
- $1.34 Billion
- Q2 2024
A detailed history of Quadrant Capital Group LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Quadrant Capital Group LLC holds 268 shares of FATE stock, worth $956. This represents 0.0% of its overall portfolio holdings.
Number of Shares
268
Previous 440
39.09%
Holding current value
$956
Previous $3,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding FATE
# of Institutions
190Shares Held
123MCall Options Held
15KPut Options Held
14K-
Redmile Group, LLC San Francisco, CA13.2MShares$47 Million2.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$37.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$36.1 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA8.22MShares$29.3 Million1.5% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.57MShares$19.9 Million0.6% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $346M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...